

Catalog # 10-4832

Larotrectinib

CAS# 1223403-58-4

(3S)-N-[5-[(2R)-2-(2,5-Difluorophenyl)pyrrolidine-1-yl]pyrazolo[1,5-a]pyrimidin-3-yl]-3-hydroxypyrrolidine-1-carboxamide; LOXO-101; ARRY-470

Lot # FBS2044

Larotrectinib is a potent (IC_{50} 's < 11 nM) inhibitor of tropomyosin receptor kinases A, B, and C (TrkA, B, and C). It is >100 fold selective against a panel of 229 kinases. Larotrectinib markedly attenuated bone cancer pain and significantly blocked the formation of neuroma-like structures and the sprouting of sensory nerve fibers. Larotrectinib caused substantial tumor regression in various cancers displaying TRK gene fusions. $^{2-4}$ Larotrectinib is the first tissue agnostic drug approved by the FDA.

- 1) Ghilardi et al. (2010), Administration of a tropomyosin receptor kinase inhibitor attenuates sarcoma-induced nerve sprouting, neuroma formation, and bone cancer pain; Mol. Pain, **6** 87
- 2) Doebele et al. (2015), An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101; Cancer Discov., **5** 1049
- 3) Landman et al. (2018), Rapid response to Larotrectinib (LOXO-101) in Adult Chemotherapy-Naïve Patients With Advanced Triple-Negative Secretory Breast Cancer Expressing ETV6-NTRK3 Fusion; Clin. Breast Cancer, 18 e267
- 4) Drilon et al. (2018), Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children; N. Engl. J. Med., 378 731

PHYSICAL DATA

Molecular Weight: 428.44

NMR: (Conforms)

Solubility: DMSO (5 mg/ml)
Physical Description: Yellow solid

Storage and Stability: Store as supplied desiccated at room temperature for up to 1 year from the date of purchase.

Solutions in DMSO may be stored at -20°C for up to 2 months.

Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications.